[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 45 of about 45
1. Melonakos EJ, Santucci RA: Treatment of low-grade bulbar transitional cell carcinoma with urethral instillation of mitomycin C. Adv Urol; 2008;:173694

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of low-grade bulbar transitional cell carcinoma with urethral instillation of mitomycin C.
  • A 63-year old man was referred to us after three rapid recurrences of low-grade urethral papillary transitional cell carcinoma of the bulbar urethra, after repeated primary excision.
  • Cystoscopy confirmed 3-4 low-grade urethral transitional cell carcinomas, which were subsequently fulgurated.
  • After urethral healing, a solution of Mitomycin C (40 mg/80 cc) was instilled into the urethra for fifteen minutes and held in place with a penile clamp.
  • Urethral instillations were repeated weekly for six weeks.
  • This case highlights the successful treatment of urethral carcinoma with topical chemotherapy, which is usually reserved for the bladder, using a slight modification of standard technique.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2006 Sep;98(3):526-31 [16925747.001]
  • [Cites] J Urol. 2000 Oct;164(4):1305 [10992392.001]
  • [Cites] J Urol. 2000 Oct;164(4):1306 [10992393.001]
  • [Cites] Urology. 1999 Jun;53(6):1126-32 [10367840.001]
  • (PMID = 18989359.001).
  • [ISSN] 1687-6369
  • [Journal-full-title] Advances in urology
  • [ISO-abbreviation] Adv Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2575232
  •  go-up   go-down


2. Morikawa H, Cho M, Takada S, Fujimoto K, Uemura H, Ozono S, Hirao Y, Natsume O: [A case of primary transitional cell carcinoma of the prostate]. Hinyokika Kiyo; 2003 Jun;49(6):357-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary transitional cell carcinoma of the prostate].
  • A 77-year-old man was referred to our hospital with a complaint of dysuria and right ischiodynia.
  • Pathological diagnosis of prostate biopsy specimen was transitional cell carcinoma with grade 3 malignancy and negative staining for PSA.
  • Endoscopic examination showed a normal appearance of bladder and prostatic urethral epithelium.
  • Endocrine therapy (goserelin acetate depot, bicalutamide) and systemic chemotherapy (methotrexate, epirubicin, cisplatin) were performed combined with irradiation to right ischium metastasis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Transitional Cell / diagnosis. Neoplasms, Multiple Primary. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Combined Modality Therapy. Fatal Outcome. Humans. Male. Prostate-Specific Antigen / blood. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12894737.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 11
  •  go-up   go-down


3. Taylor JM, Spiess PE, Kassouf W, Munsell MF, Kamat AM, Dinney CP, Grossman HB, Pisters LL: Management of urethral recurrence after orthotopic urinary diversion. BJU Int; 2010 Jul;106(1):56-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of urethral recurrence after orthotopic urinary diversion.
  • STUDY TYPE: Therapy (case series) Level of Evidence 4 OBJECTIVE To evaluate our experience with urethral recurrences in patients treated by radical cystectomy(RC) and orthotopic neobladder urinary diversion for carcinoma of the bladder.
  • RESULTS: In all, 260 patients underwent RC with a Studer or Hautmann orthotopic urinary diversion; the median (range) follow-up was 5.1 (0-15.6) years.
  • Six patients (2.3%) developed local recurrence of urothelial cancer (UC) within the urethra after this treatment.
  • The median (range) time to presentation with recurrence after RC was 2.4 (0.7-3.6) years for pT1-4 UC.
  • Recurrences were treated with various methods, including transurethral resection, urethrectomy with conversion of neobladder to continent catheterizable diversion, and chemotherapy.
  • CONCLUSIONS: In our experience, local recurrences involving the urethra are infrequent.
  • Neoadjuvant chemotherapy should be considered for recurrences with adverse clinicopathological features.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Neoplasm Recurrence, Local / surgery. Urethral Neoplasms / secondary. Urinary Bladder Neoplasms / surgery. Urinary Diversion / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Treatment Outcome. Urinary Reservoirs, Continent

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20002676.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA91846
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Kato S, Ito Y, Nishino Y, Ban Y, Deguchi T: [Urethral recurrence and distant metastases of bladder cancer 9 years after cystectomy and neobladder]. Hinyokika Kiyo; 2005 Mar;51(3):195-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urethral recurrence and distant metastases of bladder cancer 9 years after cystectomy and neobladder].
  • We report a 79-year-old female with urethral recurrence and distant metastases of urothelial bladder cancer.
  • She had undergone urethra-sparing cystectomy and orthotopic ileal neobladder at 70 years of age.
  • Chemotherapy was not performed and the patient died 5 months later.
  • We concluded that long-term follow-up for urethral recurrence in women with neobladders was necessary.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy. Lymph Nodes / pathology. Urethral Neoplasms / secondary. Urinary Bladder Neoplasms / surgery. Urinary Diversion

  • Genetic Alliance. consumer health - Urethral cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852676.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Murphy DR, Morris NJ: Transitional cell carcinoma of the urethra [correction of ureter] in a patient with buttock pain: a case report. Arch Phys Med Rehabil; 2008 Jan;89(1):150-2
Genetic Alliance. consumer health - Transitional cell carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the urethra [correction of ureter] in a patient with buttock pain: a case report.
  • This case reports on a patient with an unusual presentation of a rare tumor: urethral transitional cell carcinoma (TCC).
  • Urethral TCC occurs in approximately 0.7% to 4.0% of patients who have had primary bladder cancer.
  • The patient was initially suspected to have piriformis syndrome, but when he did not respond as expected to treatment, and because of his history of primary bladder cancer, further evaluation was undertaken and the diagnosis was made.
  • The patient responded well to radiation and chemotherapy.
  • Musculoskeletal physicians should be particularly suspicious of the presence of urethral TCC in a patient with a history of primary bladder cancer who reports low back or buttock pain, particularly if the patient does not respond quickly to treatment.
  • [MeSH-major] Carcinoma, Transitional Cell / complications. Low Back Pain / etiology. Urethral Neoplasms / complications
  • [MeSH-minor] Aged. Buttocks. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Neoplasms, Multiple Primary. Prostatic Neoplasms. Urinary Bladder Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164345.001).
  • [ISSN] 1532-821X
  • [Journal-full-title] Archives of physical medicine and rehabilitation
  • [ISO-abbreviation] Arch Phys Med Rehabil
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Nishimoto K, Oyama M, Ando T, Nakajima Y, Kiguchi H: [Inguinal lymph node metastasis of bladder carcinoma ten years after cystourethrectomy: a case report]. Hinyokika Kiyo; 2005 Nov;51(11):759-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inguinal lymph node metastasis of bladder carcinoma ten years after cystourethrectomy: a case report].
  • A 79-year-old man had undergone radical cystourethrectomy for bladder carcinoma in January, 1989.
  • Pathological report was Small cell carcinoma (SCC) >> transitional cell carcinoma (TCC), G2 > G3, pT4 (prostate), ew (-).
  • Ten years later, follow-up computed tomography (CT) revealed swollen left inguinal lymph node in October 1998 and lymph node dissection was performed in January, 2000.
  • Three couses of MVAC (methotrexate, vinblastine, doxorubicin cisplatinum) chemotherapy had been performed since September, 2001 but were in effective.
  • Papillary tumor was observed at external urethral meatus in September, 2002 and the biopsied specimens showed TCC, G1 > G2, pathologically.
  • It is suggested that the recurrent TCC tumor in the urethral remnants might metastasize into the inguinal lymph nodes.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy. Lymph Nodes / pathology. Urethra / surgery. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Humans. Inguinal Canal. Lymphatic Metastasis. Male. Time Factors

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16363710.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Arya M, Brown RS, Hayne D, Patel HR, Harland SJ: Primary anterior urethral transitional cell carcinoma: a rare tumour. Eur J Surg Oncol; 2001 Sep;27(6):607-8
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary anterior urethral transitional cell carcinoma: a rare tumour.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Urethral Neoplasms / pathology. Urethral Neoplasms / therapy
  • [MeSH-minor] Adult. Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Doxorubicin / administration & dosage. Endoscopy / methods. Follow-Up Studies. Humans. Instillation, Drug. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11520099.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  •  go-up   go-down


8. Uemura M, Nakagawa M, Mukai M, Kanno N, Nishimura K, Miyoshi S, Yoshida K, Kawano K: [A case of inguinal lymph node metastasis and urethral remnant tumor arising eight years after cystourethrectomy for bladder cancer]. Hinyokika Kiyo; 2003 Aug;49(8):471-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of inguinal lymph node metastasis and urethral remnant tumor arising eight years after cystourethrectomy for bladder cancer].
  • Eight years later, he visited our department complaining of bleeding from external urethral meatus.
  • Imaging study including computed tomographic (CT) scan and magnetic resonance imaging (MRI) showed a tumor arising from the urethral remnant and left inguinal lymph node involvement.
  • Histopathological examination revealed that both tumors were transitional cell carcinomas suggesting recurrence of bladder cancer.
  • Two courses of M-VAC chemotherapy were given as adjuvant therapy.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Carcinoma, Transitional Cell / surgery. Lymph Nodes / pathology. Urethra / surgery. Urethral Neoplasms / secondary. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Urethral cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14518384.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Canda AE, Tuzel E, Mungan MU, Yorukoglu K, Kirkali Z: Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder. Eur Urol; 2004 Apr;45(4):465-9; discussion 469-70
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder.
  • OBJECTIVE: Treatment of patients with mucosal prostatic urethral transitional cell carcinoma (TCC) is controversial.
  • In this study, we evaluated the outcome of patients with mucosal prostatic urethral TCC who were managed conservatively.
  • Initially, all patients with mucosal PU involvement without evidence of ductal and/or stromal involvement underwent intravesical BCG or Epirubicin therapy.
  • RESULTS: Nineteen patients (6.6%) had mucosal involvement of the prostatic urethra (PU) and concomitant multifocal TCC of the bladder.
  • CONCLUSIONS: Prostatic urethral sampling should be considered necessary in intermediate and high risk patients with superficial TCC of the bladder.
  • Intravesical therapy, especially with BCG seems to be an effective treatment alternative in the management of mucosal PU involvement.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. BCG Vaccine / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Epirubicin / therapeutic use. Neoplasms, Multiple Primary / drug therapy. Prostatic Neoplasms / drug therapy. Urethral Neoplasms / drug therapy. Urinary Bladder Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15041110.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antibiotics, Antineoplastic; 0 / BCG Vaccine; 3Z8479ZZ5X / Epirubicin
  •  go-up   go-down


10. Liptak JM, Brutscher SP, Monnet E, Dernell WS, Twedt DC, Kazmierski KJ, Walter CU, Mullins MN, Larue SM, Withrow SJ: Transurethral resection in the management of urethral and prostatic neoplasia in 6 dogs. Vet Surg; 2004 Sep-Oct;33(5):505-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transurethral resection in the management of urethral and prostatic neoplasia in 6 dogs.
  • OBJECTIVE: To assess cystoscopic transurethral resection (TUR) for the palliative management of dogs with neoplastic infiltration of the urethra.
  • METHODS: Cystoscopic examination and electrosurgical TUR were performed in dogs with urination difficulties caused by prostatic or urethral neoplasia.
  • Cystoscopic examination was used to determine the extent of neoplastic involvement of the urethra.
  • TUR involved piecemeal removal of neoplastic tissue from the urethral lumen using an electrocautery cutting loop.
  • Hemorrhage was controlled with a cystoscopic cauterized roller-ball.
  • In 2 male dogs, intraoperative radiation therapy (IORT) was used to treat both prostatic neoplasia and the sublumbar lymph node bed.
  • Surgical technique, complications, adjuvant treatment, and outcome were recorded.
  • RESULTS: TUR was performed in 3 male dogs with prostatic carcinoma and 2 female dogs with urethral transitional cell carcinoma (TCC).
  • Iatrogenic urethral perforation occurred during TUR in 3 dogs.
  • Treatment-related complications included urinary tract infection and tumor seeding.
  • CONCLUSIONS: TUR (in combination with chemotherapy+/-IORT) resulted in rapid palliation of urination difficulties in male dogs with prostatic carcinoma.
  • In female dogs with urethral TCC, however, electrosurgical TUR cannot be recommended because of a high intra- and postoperative complication rate with no improvement in postoperative management compared with historical reports of tube cystostomy.
  • CLINICAL RELEVANCE: TUR is a novel alternative for the palliation of male dogs with prostatic carcinoma.
  • In female dogs with urethral TCC, electrosurgical TUR does not provide any advantages compared with tube cystostomy.
  • [MeSH-major] Carcinoma, Transitional Cell / veterinary. Dog Diseases / surgery. Electrosurgery / veterinary. Prostatic Neoplasms / veterinary. Urethral Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15362989.001).
  • [ISSN] 0161-3499
  • [Journal-full-title] Veterinary surgery : VS
  • [ISO-abbreviation] Vet Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. VanderMolen LA, Sheehy PF, Dillman RO: Successful treatment of transitional cell carcinoma of the urethra with chemotherapy. Cancer Invest; 2002;20(2):206-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of transitional cell carcinoma of the urethra with chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Urethral Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11901541.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


12. Huncharek M, McGarry R, Kupelnick B: Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res; 2001 Jan-Feb;21(1B):765-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
  • BACKGROUND: The impact of in tranvesical chemotherapy on preventing recurrence of superficial transitional cell carcinoma of the bladder is controversial.
  • The objective of this report is to present a meta-analysis of the available clinical trial data to quantify the effect of intravesical chemotherapy on tumor recurrence following trans-urethral resection (TURB) in patients with recurrent superficial bladder cancer.
  • METHODS: A prospective study protocol outlining a meta-analysis was developed followed by a thorough search of the existing published literature using strict eligibility criteria.
  • RESULTS: Combining all 8 studies using 1 year recurrence as the outcome measure yielded a Peto odds ratio (ORp) of 0.62, demonstrating a 38% reduction in one year recurrence among patients treated with intravesical chemotherapy versus TURB alone.
  • Using 2 and 3 year recurrence as the outcome measure yielded ORp's of 0.46 and 0.35 respectively, favoring TURB + intravesical chemotherapy versus TURB alone.
  • Sensitivity analyses showed that drug type appeared to account for the observed heterogeneity with a stratified analysis demonstrating that adriamycin is less effective in reducing subsequent tumor recurrences than all other drugs studied.
  • CONCLUSION: Intravesical chemotherapy appears to have a major impact on decreasing the chance of recurrence of recurrent superficial bladder cancer.
  • These data are in contrast to prior analyses suggesting only modest efficacy of such treatment in this clinical setting.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Transitional Cell / drug therapy. Neoplasm Recurrence, Local / prevention & control. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Clinical Trials as Topic. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Epirubicin / administration & dosage. Epirubicin / therapeutic use. Follow-Up Studies. Humans. Mitomycin / administration & dosage. Mitomycin / therapeutic use. Odds Ratio. Prospective Studies. Randomized Controlled Trials as Topic. Teniposide / administration & dosage. Teniposide / therapeutic use. Thiotepa / administration & dosage. Thiotepa / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11299841.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin; 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; 905Z5W3GKH / Thiotepa; 957E6438QA / Teniposide
  •  go-up   go-down


13. Cruz Guerra NA, del Valle Manteca A, Zamora Martínez T, Tarroc Blanco A: [Metacronous transitional cell carcinoma of the prostatic urethra in a patient with history of nephroureterectomy for upper urinary tract urothelial tumor]. Arch Esp Urol; 2004 Dec;57(10):1125-7
Genetic Alliance. consumer health - Transitional cell carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metacronous transitional cell carcinoma of the prostatic urethra in a patient with history of nephroureterectomy for upper urinary tract urothelial tumor].
  • [Transliterated title] Carcinoma transicional de uretra prostatica meta-crónico en paciente con antecedente de nefroureterectomía por tumor uroteual del tracto urinario superior.
  • OBJECTIVES: We report one case of Metacronous transitional cell carcinoma (TCC) of the prostatic urethra in a patient with history of left nephroureterectomy 22 years before for urothelial neoplasia of the upper urinary tract.
  • METHODS: We describe the case of a 56-year-old male patient who presents with oligosymptomatic hematuria for several months.
  • Cystourethroscopy showed irregular hyperemic lesions in the prostatic urethra, cold biopsy of which showed urothelial atypia.
  • Pathology report of fragments of a posterior transurethral resection (TUR) was compatible with high-grade superficial transitional cell neoplasia.
  • Chemotherapy did not achieve significant results.
  • CONCLUSIONS: We emphasize the notable metachronous character of the transitional cell carcinoma of the prostatic urethra with respect to the upper urinary tract TCC.
  • We also point out the metastasic capacity of these neoplasias, as well as the bad prognosis of those cases in which chemotherapy is not effective.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Neoplasms, Second Primary / diagnosis. Urethral Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714851.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


14. Lerner SP, Colen J, Shen S: Prostatic biology, histologic patterns and clinical consequences of transitional cell carcinoma. Curr Opin Urol; 2008 Sep;18(5):508-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic biology, histologic patterns and clinical consequences of transitional cell carcinoma.
  • PURPOSE OF REVIEW: To review the current fund of knowledge about prostatic transitional cell carcinoma and the implications for diagnostic and management strategies particularly as they relate to radical cystectomy.
  • RECENT FINDINGS: Prostatic transitional cell carcinoma (TCC) is present in up to 48% of patients undergoing radical cystoprostatectomy.
  • Transurethral resection biopsies of the prostatic urethra are a sensitive means of detecting prostatic TCC and whole-mount step sectioning is the most accurate method for determining the presence and extent of prostatic TCC.
  • Preoperative detection of prostatic TCC enables accurate staging and treatment planning, including assessment of the risk of cancer at the apical urethral margin and the risk of a second primary tumor of the retained urethra, all of which factor into decision-making around urinary diversion and urethrectomy.
  • Recognition of true T4a stage requires consideration of neoadjuvant chemotherapy and the need for extended pelvic and iliac lymphadenectomy in order to optimize an integrated treatment strategy.
  • In patients with recurrent high-grade nonmuscle invasive cancer and patients undergoing radical cystoprostatectomy, a thorough assessment of the prostatic urethra and stroma is imperative for accurate staging and treatment planning.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Prostate / pathology. Prostatic Neoplasms / secondary. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Cystectomy. Humans. Male. Urethra / pathology. Urethra / surgery. Urethral Neoplasms / secondary. Urethral Neoplasms / surgery


15. Parada D, Páez A, Acosta M, Caricote L, Trujillo E, Luigi JC, Farías RM: [Primary urothelial carcinoma of the bulbomembranous urethra. Histologic and immunohistochemical study of a case]. Arch Esp Urol; 2003 Dec;56(10):1144-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary urothelial carcinoma of the bulbomembranous urethra. Histologic and immunohistochemical study of a case].
  • [Transliterated title] Carcinoma urotelial primario de uretra bulbomembranosa. Estudio histológico e inmunohistoquímico de un caso.
  • OBJECTIVE: We report a case of a primary urothelial carcinoma of the bulbomembranous urethra, with special emphasis on histopathological and immunohistochemical findings.
  • METHODS/RESULTS: A 63-year-old man presented urethral obstruction symptoms.
  • A radical phalectomy was performed and a 4.5 x 4 cm bulbomembranous urethral tumor was observed.
  • Histopathological analysis disclosed an urothelial carcinoma, that showed positive immunostaining for cytokeratin AE1/AE3, cytokeratin 7, carcinoembrionic antigen and epithelial membrane antigen.
  • The patient received radiotherapy and adjuvant chemotherapy and is currently free of disease.
  • CONCLUSION: Posterior male urothelial carcinoma of the urethra is a rare neoplasm that usually is mistaken clinically for a benign lesion.
  • The diagnostic is generally made in advanced stages with a poor therapeutical response.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Urethral Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14763421.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


16. Freiha F, Srinivas S: Invasive renal pelvis transitional cell carcinoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):4694

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive renal pelvis transitional cell carcinoma.
  • : 4694 Background: Upper tract tumors of the renal pelvis and ureter represent a small proportion of patients with transitional cell carcinoma.
  • We report our experience with invasive renal pelvis and proximal ureter transitional cell carcinoma.
  • Of the 37 patients, 13 were ineligible (6= distal ureters; 3=non invasive cancers; 1=urethral cancer; 1=co existing lung cancer; 2=no follow up).
  • In those patients without nodal metastases, the T stage determined prognosis.
  • Adjuvant chemotherapy in this small series did not have an impact on survival.
  • Early detection and adjuvant chemotherapy may have an impact and should be studied in larger number of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015643.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Palou J, Baniel J, Klotz L, Wood D, Cookson M, Lerner S, Horie S, Schoenberg M, Angulo J, Bassi P: Urothelial carcinoma of the prostate. Urology; 2007 Jan;69(1 Suppl):50-61
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urothelial carcinoma of the prostate.
  • This study was conducted to explore the diagnosis and management of urothelial carcinoma of the prostate in superficial disease and carcinoma in situ, stromal invasion, primary urothelial carcinoma, and urethral recurrence after radical surgery.
  • A consensus conference convened by the World Health Organization (WHO) and the Société Internationale d'Urologie (SIU) reviewed the diagnosis and management of urothelial carcinoma of the bladder.
  • English-language literature about urothelial carcinoma of the prostate was identified and reviewed.
  • Evidence-based recommendations for the diagnosis and management of urothelial carcinoma were made.
  • Many recommendations were level 3 or 4 citations involving the diagnosis and management of superficial urothelial carcinoma; a few were level 2 citations.
  • Level 1 citations related only to chemotherapy and radiotherapy in patients with stromal invasion, although these were not related specifically to invasive prostatic involvement.
  • Published reports on the diagnosis and treatment of superficial urothelial disease of the prostate primarily consist of short case series from individual centers.
  • [MeSH-major] Carcinoma, Transitional Cell. Prostatic Neoplasms
  • [MeSH-minor] Diagnosis, Differential. Global Health. Humans. Incidence. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Prognosis. Prostatectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17280908.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 65
  •  go-up   go-down


18. Hakenberg OW, Franke HJ, Froehner M, Wirth MP: The treatment of primary urethral carcinoma--the dilemmas of a rare condition: experience with partial urethrectomy and adjuvant chemotherapy. Onkologie; 2001 Feb;24(1):48-52
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of primary urethral carcinoma--the dilemmas of a rare condition: experience with partial urethrectomy and adjuvant chemotherapy.
  • BACKGROUND: Primary urethral carcinoma is a very rare condition, and no large-scale experience with such cases has been published.
  • Treatment will therefore have to follow rules established for the treatment of similar conditions.
  • PATIENTS: Six cases of primary urethral carcinoma (5 male, 1 female) who had been treated at our institution between 1995 and 1999 were retrospectively analyzed.
  • In 3 male cases, a primary urothelial carcinoma of the distal urethra was treated by distal urethrectomy only.
  • In 3 other cases with locally advanced tumors and/or lymph node metastases surgical treatment was followed by adjuvant cisplatinum-containing chemotherapy.
  • RESULTS: In the 3 cases with distal urethral carcinoma, partial urethrectomy with preservation of the penis resulted in cure, with a follow-up of 12-71 months.
  • In the cases with advanced disease, adjuvant chemotherapy after surgery has resulted in complete remissions in all 3 cases, with a follow-up of 4-47 months at present.
  • CONCLUSIONS: In localized, noninvasive carcinoma of the distal male urethra, partial urethrectomy seems adequate and the avoidance of penile amputation justified.
  • In advanced cases, after local excision and lymphadenectomy adjuvant chemotherapy which by necessity must follow the guidelines established for the treatment of other urothelial or squamous cell malignancies seems to be beneficial.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / surgery. Urethral Neoplasms / surgery
  • [MeSH-minor] Adult. Biopsy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Urethra / pathology. Urethra / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger GmbH, Freiburg
  • (PMID = 11441281.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Upton ML, Tangner CH, Payton ME: Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma. J Am Vet Med Assoc; 2006 Feb 15;228(4):549-52
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma.
  • CASE DESCRIPTION: 8 dogs that underwent carbon dioxide (CO2) laser ablation of transitional cell carcinoma in the bladder trigone and proximal portion of the urethra and were also treated with mitotranxone and piroxicam.
  • CLINICAL FINDINGS: Transitional cell carcinoma of the bladder frequently involves the trigone and urethra and can be difficult to manage surgically.
  • Dogs underwent laser ablation of the primary tumor and were treated with mitoxantrone at a dosage of 5 mg/m2)every 3 weeks for 4 treatments.
  • TREATMENT AND OUTCOME: Median and mean disease-free intervals were 200 and 280 days, respectively.
  • Median and mean survival times were 299 and 411 days, respectively.
  • Adverse treatment effects were observed in 2 dogs; signs included mild, self-limiting inappetance and lethargy.
  • The procedure appeared to be well tolerated; all treated dogs had rapid resolution of clinical signs of disease of the lower portion of the urinary tract.
  • CLINICAL RELEVANCE: Although survival times achieved with CO2 laser ablation and treatment with mitoxantrone and piroxicam were similar to survival times associated with chemotherapy alone, resolution of clinical signs was better with the combined treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Transitional Cell / veterinary. Dog Diseases / drug therapy. Dog Diseases / surgery. Laser Therapy / veterinary. Urethral Neoplasms / veterinary. Urinary Bladder Neoplasms / veterinary
  • [MeSH-minor] Animals. Carbon Dioxide. Combined Modality Therapy. Disease-Free Survival. Dogs. Female. Male. Mitoxantrone / adverse effects. Mitoxantrone / therapeutic use. Piroxicam / adverse effects. Piroxicam / therapeutic use. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16478428.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 13T4O6VMAM / Piroxicam; 142M471B3J / Carbon Dioxide; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


20. Zhang Q, Fu S, Liu T, Peng L, Huang G, Lu JJ: Adjuvant intraoperative electron radiotherapy and external beam radiotherapy for locally advanced transitional cell carcinoma of the ureter. Urol Oncol; 2009 Jan-Feb;27(1):14-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant intraoperative electron radiotherapy and external beam radiotherapy for locally advanced transitional cell carcinoma of the ureter.
  • OBJECTIVE: Surgery is the mainstay treatment for transitional cell carcinoma (TCC) of the ureter; however, local recurrence remains a common cause of treatment failure for locally advanced disease after surgery, and the benefit of adjuvant radiotherapy has not been completely determined.
  • The objective of this analysis was to evaluate the outcome of postsurgical high dose radiotherapy consisting of intraoperative electron beam radiotherapy (IOERT) and external beam radiotherapy (EBRT) in locally advanced transitional cell carcinoma of the ureter.
  • The dose of IOERT ranged between 10 to 20 Gy (median 14 Gy).
  • Conventional EBRT given with the total dose ranged between 36 and 45 Gy (median 42 Gy).
  • Chemotherapy was utilized in 10 of the 17 patients at the discretion of their primary oncologist.
  • Adjuvant IOERT appears to permit dose escalation safely in patients who received conventional adjuvant EBRT and chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / radiotherapy. Electrons / therapeutic use. Radiotherapy, Adjuvant / methods. Urethral Neoplasms / radiotherapy. Urethral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Male. Medical Oncology / methods. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18367127.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


21. Cresswell J, Roberts JT, Neal DE: Urethral recurrence after radical radiotherapy for bladder cancer. J Urol; 2001 Apr;165(4):1135-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urethral recurrence after radical radiotherapy for bladder cancer.
  • PURPOSE: Following cystectomy for bladder cancer, orthotopic reconstruction may result in a decreased risk of urethral recurrence compared to cutaneous diversion.
  • We evaluate the rate of urethral recurrence after radical external beam radiotherapy.
  • Patients treated with chemotherapy were excluded from study.
  • Urethral recurrence developed in 7 (3.2%) cases and was detected within 18 months (median 10 months, range 3 months to 5 years) of followup in 5.
  • In 2 of these 7 cases recurrence developed in the prostatic urethra, and when these 2 cases were excluded from analysis the recurrence rate decreased to 2.3%.
  • A total of 64 men completed 5-year followup, with a 4.7% rate of urethral recurrence (3.1% excluding prostatic urethral recurrence).
  • Multifocal disease, bladder neck involvement, prostatic disease and cis were possible risk factors for urethral recurrence.
  • CONCLUSIONS: The risk of urethral recurrence after radical radiotherapy for transitional cell carcinoma of the bladder is comparable with that reported after orthotopic reconstruction.
  • [MeSH-major] Carcinoma, Transitional Cell / radiotherapy. Neoplasm Recurrence, Local / prevention & control. Urethral Neoplasms / prevention & control. Urinary Bladder Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Urethral cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11257654.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Taylor JH, Davis J, Schellhammer P: Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra. Clin Genitourin Cancer; 2007 Sep;5(6):386-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
  • BACKGROUND: Intravesical bacillus Calmette-Guérin (BCG) is a treatment option for superficial (<or=T1) transitional cell carcinoma.
  • Transitional cell carcinoma involving the prostatic urethra presents a treatment dilemma.
  • Whereas prostatic urethral involvement might require radical cystectomy, select patients can be offered BCG and careful surveillance to preserve the bladder.
  • PATIENTS AND METHODS: Twenty-eight patients with high-risk superficial bladder cancer and prostatic urethral involvement were treated with once-weekly BCG for 6 weeks.
  • Twenty-eight percent (8 of 28 patients) underwent cystectomy because of failure of treatment to eradicate superficial disease or disease progression.
  • CONCLUSION: Our long-term data support the durability of intravesical BCG in select patients with superficial bladder transitional cell carcinoma with prostatic urethral involvement.
  • Follow-up biopsy of the prostatic urethra is mandatory and, if positive, cystectomy is indicated.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. BCG Vaccine / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Prostatic Neoplasms / drug therapy. Urethral Neoplasms / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Cystoscopy. Diagnosis, Differential. Follow-Up Studies. Humans. Instillation, Drug. Male. Neoplasm Staging. Transurethral Resection of Prostate. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17956711.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  •  go-up   go-down


23. Varol C, Thalmann GN, Burkhard FC, Studer UE: Treatment of urethral recurrence following radical cystectomy and ileal bladder substitution. J Urol; 2004 Sep;172(3):937-42
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of urethral recurrence following radical cystectomy and ileal bladder substitution.
  • PURPOSE: With the introduction of orthotopic bladder substitution after radical cystectomy in patients with invasive bladder cancer urethral recurrences have become a therapeutic challenge.
  • MATERIALS AND METHODS: We retrospectively evaluated our patients with urethral recurrences treated with a urethra sparing approach after orthotopic bladder substitution.
  • Depending on the extension of recurrence and eventual concomitant metastases patients were treated with urethrectomy, no treatment, systemic chemotherapy or intraurethral bacillus Calmette-Guerin (BCG).
  • Three times the common dose of BCG (ImmuCyst, Aventis, Paris, France or OncoTICE, Organon, West Orange, New Jersey) in 150 ml NaCl 0.9% was used for intraurethral BCG perfusion therapy according to an institutional protocol using a modified Foley catheter.
  • RESULTS: Between 1985 and 2001, 15 of 371 patients (4%) who received an orthotopic bladder substitute had urethral recurrence.
  • Two patients were treated with systemic chemotherapy (methotrexate, vinblastine, doxorubicin and cisplatin) alone due to metastatic disease and 10 received intraurethral BCG therapy.
  • Five of 6 patients (83%) with carcinoma in situ remained free of recurrence following treatment with BCG, while in 4 with papillary or invasive disease treatment failed.
  • Three patients underwent urethrectomy, including 2 following failed BCG therapy for papillary disease.
  • CONCLUSIONS: Carcinoma in situ urethral recurrence following orthotopic bladder substitution can be treated successfully with intraurethral BCG perfusion therapy in approximately 80% of patients.
  • However, papillary and invasive transitional cell urethral recurrence should be treated with urethrectomy.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Carcinoma, Transitional Cell / therapy. Cystectomy. Urethral Neoplasms / secondary. Urethral Neoplasms / therapy. Urinary Bladder Neoplasms / surgery. Urinary Reservoirs, Continent
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. BCG Vaccine / administration & dosage. Humans. Male. Middle Aged. Urethra / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15311003.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCG Vaccine
  •  go-up   go-down


24. Ruoppolo M, Gozo M, Milesi R, Spina R, Fragapane G: [Urethral recurrence of invasive carcinoma following BCG treatment for bladder Ca in situ]. Urologia; 2010 Oct-Dec;77 Suppl 17:72-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urethral recurrence of invasive carcinoma following BCG treatment for bladder Ca in situ].
  • [Transliterated title] Recidiva uretrale di Ca infiltrante dopo trattamento con BCG per Ca in situ vescicale.
  • CIS is a flat, high-grade, non-invasive microscopic urothelial carcinoma.
  • CIS is classified as primary, secondary or concurrent, when occurred as isolated CIS without cuncurrent papillary tumors, or detected during the follow-up of patients with a previous papillary tumor, or finally in the presence of bladder neoplasm.
  • BCG is widely established as the treatment of choice for CIS with a success rate of approximately 70%.
  • BCG reduces the risk of progression of CIS into invasive carcinoma in 30 to 50% of cases.
  • Direct and prolonged contact between the urothelium and BCG is a prerequisite for successful therapy.
  • Discovery of CIS in the prostatic or membranous urethra represents an ominous sign.
  • CIS may be present only in the epithelial lining of the prostatic urethra or in the ducts, or in the worst case it may be found in the prostatic tissue stroma.
  • Urethral involvement by CIS is at high risk of tumor progression and development of metastases due to reduced thickness of lamina propria and absence of muscolaris mucosa.
  • 83 patients, enrolled from 1/1996 to 12/2005 at our urological department with CIS: primary (focal and multifocal) in 25, secondary in 7 and cuncurrent in 51 (associated with T1bG3 cancer in 37 cases), and urethral CIS in 5 and conservatively treated by TUR and intravescical instillations of BCG, 4 developed afterwords only invasive cancer of the urethra in the absence of bladder involvement.
  • In 2 cases cancer arised from the prostatic fossa after TURP, in 1 from membranous urethra and in the last from prostatic ducts.
  • Among the 4 patients, 3 were treated by cystoprostatourethrectomy and Platinum-based chemotherapy, 1 refused surgical treatment.
  • We conclude that prostatic/urethral involvement during follow-up after successful intravesical treatment with BCG in CIS represents a high risk of developing invasive and incontrolled cancer.
  • [MeSH-major] BCG Vaccine / therapeutic use. Carcinoma in Situ / therapy. Carcinoma, Transitional Cell / secondary. Urethral Neoplasms / secondary. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Cystectomy / methods. Disease Progression. Female. Follow-Up Studies. Humans. Immunotherapy. Male. Neoplasm Invasiveness. Organoplatinum Compounds / administration & dosage. Prostatectomy / methods. Prostatic Neoplasms / secondary. Risk. Treatment Outcome. Urethra / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308679.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine; 0 / Organoplatinum Compounds
  •  go-up   go-down


25. Dimarco DS, Dimarco CS, Zincke H, Webb MJ, Bass SE, Slezak JM, Lightner DJ: Surgical treatment for local control of female urethral carcinoma. Urol Oncol; 2004 Sep-Oct;22(5):404-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment for local control of female urethral carcinoma.
  • We reviewed 53 patients (mean age 63 years) who underwent partial urethrectomy (n = 26) or radical extirpation (n = 27) for primary female urethral cancer from 1948 through 1999.
  • Clinical stage, histology, high pathologic stage (3 or 4) and grade, tumor location, nodal status, surgery type, adjuvant therapy, and treatment decade were candidate outcome predictors.
  • The predominant carcinomas were squamous cell (n = 21), transitional cell (TCC) (n = 15), and adenocarcinoma (n = 14).
  • For adjuvant therapy, 20 patients had radiation (8 preoperatively), 2 had radiation + chemotherapy, and 1 had chemotherapy alone.
  • Of patients undergoing partial urethrectomy for pT1-3 tumors, 6/27 (22%) had urethral recurrence.
  • Recurrence-free survival +/- standard error (SE) at 10 years was 45 + 8%.
  • Upon review, partial urethrectomy resulted in a high urethral recurrence rate (22%) with no bladder recurrences.
  • [MeSH-major] Carcinoma / surgery. Neoplasm Recurrence, Local. Urethral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Sex Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15464921.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Osai WE, Ng CS, Pagliaro LC: Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma. Anticancer Drugs; 2008 Apr;19(4):427-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma.
  • We report the case of a 78-year-old man with metastatic transitional-cell carcinoma with squamous differentiation that responded dramatically to the monoclonal antibody agent, bevacizumab.
  • The tumor originated in the bulbar urethra, with histology of poorly differentiated urothelial carcinoma.
  • Metastasis to a right inguinal lymph node was biopsy-confirmed as transitional-cell carcinoma with areas of keratinization.
  • At last follow-up, he had received 24 months of bevacizumab treatment with minimal toxicity and a positive response.
  • Mediators of angiogenesis have been implicated in the clinical progression of bladder cancer, although the role of angiogenesis inhibitors as treatment has not yet been defined.
  • The striking benefit achieved in this heavily treated patient suggests that bevacizumab could have clinically useful antitumor activity in advanced urothelial carcinoma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Drug Resistance, Neoplasm. Urethral Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18454053.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


27. Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA, European Association of Urology: [Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma]. Actas Urol Esp; 2010 Jan;34(1):51-62
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma].
  • [Transliterated title] Actualización de las Guías Clínicas de la Asociación Europea de Urología sobre el carcinoma vesical músculo-invasivo y metastásico.
  • CONTEXT: New data regarding diagnosis and treatment of muscle-invasive and metastatic bladder cancer (MiM-BC) has emerged and led to an update of the European Association of Urology (EAU) guidelines for MiM-BC.
  • EVIDENCE ACQUISITION: A comprehensive workup of the literature obtained from Medline, the Cochrane central register of systematic reviews, and reference lists in publications and review articles was developed and screened by a group of urologists, oncologists, and radiologist appointed by the EAU Guideline Committee.
  • EVIDENCE SYNTHESIS: The diagnosis of muscle-invasive bladder cancer (BCa) is made by transurethral resection (TUR) and following histopathologic evaluation.
  • Patients with confirmed muscle-invasive BCa should be staged by computed tomography (CT) scans of the chest, abdomen, and pelvis, if available.
  • Adjuvant chemotherapy is currently only advised within clinical trials.
  • Radical cystectomy (RC) is the treatment of choice for both sexes, and lymph node dissection should be an integral part of cystectomy.
  • An orthotopic bladder substitute should be offered to both male and female patients lacking any contraindications, such as no tumour at the level of urethral dissection.
  • Multimodality bladder-preserving treatment in localised disease is currently regarded only as an alternative in selected, well-informed, and compliant patients for whom cystectomy is not considered for clinical or personal reasons.
  • c) functional deterioration at particular sites; and d) consideration of treatment of a recurrence.
  • In metastatic disease, the first-line treatment for patients fit enough to sustain cisplatin is cisplatin-containing combination chemotherapy.
  • Presently, there is no standard second-line chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Urinary Bladder Neoplasms. Urology / standards
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Cystectomy / methods. Diagnostic Imaging. Evidence-Based Medicine. Female. Humans. Lymph Node Excision. Male. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Staging / methods. Palliative Care. Risk Factors. Urinary Diversion / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223133.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Practice Guideline
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


28. Kouno T, Ando M, Yonemori K, Matsumoto K, Shimizu C, Katsumata N, Komiyama M, Okajima E, Matsuoka N, Fujimoto H, Fujiwara Y: Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur Urol; 2007 Oct;52(4):1115-22
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.
  • OBJECTIVE: Weekly administration of paclitaxel plus carboplatin is hypothesized to be an effective second-line treatment for advanced transitional cell cancer after failure of platinum-based regimen.
  • PATIENTS AND METHODS: Patients with advanced transitional cell cancer who showed evidence of progressive or recurrent disease after methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) therapy were eligible for this study.
  • The median progression-free survival (PFS) and median survival times were 3.7 and 7.9 mo, respectively.
  • Among the 22 patients who received prior MVAC therapy for metastatic disease, 36% had an objective response; their median PFS and median survival times were 4.3 and 7.9 mo, respectively; neither survival time significantly differed from the survival time of those who received prior MVAC as adjuvant setting.
  • CONCLUSIONS: Weekly paclitaxel plus carboplatin was a manageable, active second-line treatment for advanced transitional cell cancer after failure of platinum-based therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Kidney Neoplasms / drug therapy. Urethral Neoplasms / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Carboplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Kidney Pelvis. Male. Middle Aged. Paclitaxel / administration & dosage. Patient Selection. Platinum Compounds / therapeutic use. Survival Analysis. Survivors. Treatment Failure

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2007 Oct;52(4):1122 [17433856.001]
  • (PMID = 17433855.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Platinum Compounds; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


29. Tamada S, Omachi T, Ito T, Kawashima H, Nakatani T: [Primary urothelial carcinoma with sarcomatous transformation of the prostate]. Nihon Hinyokika Gakkai Zasshi; 2010 Jul;101(5):698-702
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary urothelial carcinoma with sarcomatous transformation of the prostate].
  • A small papillary tumor at the prostatic urethra was found by cystourethroscopy.
  • Then, we performed transurethral resection of the tumor and trans-perineal needle biopsy of the prostate, and diagnosed him as primary urothelial carcinoma of the prostate.
  • Following neo-adjuvant chemotherapy(MVAC), the patient was treated with radical cystoprostatectomy.
  • The histopathological examination showed urothelial carcinoma with concomitant sarcomatous transformation.
  • He was treated with the second-line chemotherapy using paclitaxel and gemcitabin combined with the radiation therapy, resulting in the disappearance of the tumor.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / therapy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy. Sarcoma / pathology. Sarcoma / therapy. Urethral Neoplasms / pathology. Urethral Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Cystectomy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Male. Middle Aged. Neoplasm Invasiveness. Paclitaxel / administration & dosage. Prostatectomy. Radiotherapy, Adjuvant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20715503.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


30. Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF: Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs; 2007 Jun;25(3):265-70
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.
  • PURPOSE: The purpose of this single-center phase II study was to determine the activity of pemetrexed administered as second-line therapy in patients with advanced urothelial carcinoma.
  • METHODS: Patients with advanced urothelial carcinoma that had relapsed after receiving perioperative chemotherapy, or progressed on first-line chemotherapy for metastatic disease, were eligible for enrollment.
  • Treatment was generally well tolerated, however, 2/13 patients developed febrile neutropenia.
  • CONCLUSIONS: Pemetrexed as second-line therapy in advanced urothelial carcinoma is associated with modest activity.
  • The role of this novel antifolate in chemotherapy-naïve patients warrants further investigation.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Glutamates / therapeutic use. Guanine / analogs & derivatives. Pelvic Neoplasms / drug therapy. Salvage Therapy. Urethral Neoplasms / drug therapy. Urinary Bladder Neoplasms / drug therapy. Urothelium / pathology
  • [MeSH-minor] Administration, Oral. Drug Administration Schedule. Folic Acid / administration & dosage. Folic Acid / therapeutic use. Humans. Infusions, Intravenous. Pemetrexed. Treatment Outcome. Vitamin B 12 / administration & dosage. Vitamin B 12 / therapeutic use. Vitamin B Complex / administration & dosage. Vitamin B Complex / therapeutic use

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 18):69-75 [12571815.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1853-7 [9164195.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Mol Cancer Ther. 2002 May;1(7):545-52 [12479273.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1208-12 [9849481.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1395-401 [16622447.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3173-81 [10506615.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):589-93 [9053481.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):937-40 [11844814.001]
  • [Cites] Cancer. 2006 Aug 1;107(3):506-13 [16773629.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1589-97 [15117980.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1627-32 [16138364.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3451-7 [16849761.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Apr;57(4):427-35 [16322992.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):552-62 [16391300.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • (PMID = 17146733.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 12001-76-2 / Vitamin B Complex; 5Z93L87A1R / Guanine; 935E97BOY8 / Folic Acid; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


31. Dalbagni G, Donat SM, Eschwège P, Herr HW, Zelefsky MJ: Results of high dose rate brachytherapy, anterior pelvic exenteration and external beam radiotherapy for carcinoma of the female urethra. J Urol; 2001 Nov;166(5):1759-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of high dose rate brachytherapy, anterior pelvic exenteration and external beam radiotherapy for carcinoma of the female urethra.
  • PURPOSE: We evaluated a multimodality approach to locally advanced urethral carcinoma in women.
  • MATERIALS AND METHODS: Between August 1996 and July 1999, 6 women were treated for locally advanced carcinoma of the urethra with anterior pelvic exenteration followed by high dose 192iridium intraoperative radiation therapy.
  • Four of the 6 patients were also treated with neoadjuvant or concomitant platinum based chemotherapy.
  • [MeSH-major] Brachytherapy. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / surgery. Pelvic Exenteration. Urethral Neoplasms / radiotherapy. Urethral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Humans. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11586218.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Matos T, Cufer T, Cervek J, Bornstnar S, Kragelj B, Zumer-Pregelj M: Prognostic factors in invasive bladder carcinoma treated by combined modality protocol (organ-sparing approach). Int J Radiat Oncol Biol Phys; 2000 Jan 15;46(2):403-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in invasive bladder carcinoma treated by combined modality protocol (organ-sparing approach).
  • PURPOSE: The results of bladder sparing approach for the treatment of muscle-invasive bladder cancer, using a combination of transurethral resection (TUR), chemotherapy, and radiotherapy, are encouraging.
  • The aim of our study was to find out which pretreatment characteristics influence the survival of patients treated by organ sparing approach that would enable us to identify the patients most suitable for this type of treatment.
  • METHODS AND MATERIALS: The prognostic value of different factors, such as age, gender, performance status, hemoglobin level, clinical stage, histologic grade, presence of obstructive uropathy, and completeness of TUR, has been studied in 105 patients with invasive bladder cancer, who received a bladder sparing treatment in the period from 1988 to 1995.
  • They were treated with a combination of TUR, followed by 2-4 cycles of methotrexate, cisplatinum, and vinblastine polychemotherapy.
  • In complete responders the treatment was completed by radiotherapy (50 Gy to the bladder and 40 Gy to the regional lymph nodes), whereas nonresponders underwent cystectomy whenever feasible.
  • We believe that performance status best reflects the extent of disease and exerts significant influence on the extent and course of treatment, while obstructive uropathy is a good indicator of local spread of the disease, better than clinical T-stage.
  • CONCLUSION: Patients with muscle-invasive bladder cancer who are most likely to benefit from conservative treatment approach include those with good performance status, absence of hydronephrosis, and histologic low grade transitional cell carcinoma.
  • [MeSH-major] Carcinoma, Transitional Cell / therapy. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / blood. Carcinoma / pathology. Carcinoma / therapy. Combined Modality Therapy. Female. Follow-Up Studies. Hemoglobin A / analysis. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Severity of Illness Index. Sex Factors. Urethral Obstruction / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10661347.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 9034-51-9 / Hemoglobin A
  •  go-up   go-down


33. Davis JW, Sheth SI, Doviak MJ, Schellhammer PF: Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup. J Urol; 2002 Feb;167(2 Pt 1):494-500; discussion 501
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup.
  • PURPOSE: Intravesical bacillus Calmette-Guerin (BCG) treatment of high risk superficial bladder cancer has reduced recurrence and progression, and lengthened disease specific survival.
  • However, documentation of treatment durability is limited.
  • MATERIALS AND METHODS: Between 1981 and 1989, 98 patients with high risk or recurrent transitional cell carcinoma were treated with complete transurethral resection followed by 1 or more 6-week induction courses of BCG, and were followed through 2000.
  • A total of 44 cases were carcinoma in situ plus or minus papillary and 35 were stage T1, which was assigned only if muscularis propria free of tumor was present on the biopsy specimen.
  • RESULTS: Of 98 patients with minimum followup greater than 10 years disease progressed to stage T2 or greater in 27 at a median of 30.7 months (range 1.2 to 143.7), of whom cystectomy was performed in 16, cystectomy for recurrent high risk Ta/T1 disease was required in 10, death from transitional cell carcinoma occurred in 13 at a median of 69.7 months (range 11 to 135), upper tract tumor developed in 13 at a median of 49 months (range 9 to 146) and there was evidence of prostatic urethral involvement in 21.
  • The 10-year progression-free survival was 67%, and progression-free survival with a retained bladder 59%.
  • CONCLUSIONS: After complete tumor resection and careful pathological staging intravesical BCG for high risk and/or recurrent superficial bladder carcinoma resulted in overall progression-free and disease specific survival rates that support this bladder sparing strategy.
  • Patients must be followed closely and cystectomy recommended for those with an initial incomplete response after initial therapy or recurrent high risk disease.
  • [MeSH-major] BCG Vaccine / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11792905.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine
  •  go-up   go-down


34. Schenkman E, Lamm DL: Superficial bladder cancer therapy. ScientificWorldJournal; 2004 Jun 28;4 Suppl 1:387-99
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial bladder cancer therapy.
  • Bladder cancer treatment remains a challenge despite significant improvements in preventing disease progression and improving survival.
  • Intravesical therapy has been used in the management of superficial transitional cell carcinoma (TCC) of the urinary bladder (i.e.
  • Ta, T1, and carcinoma in situ) with specific objectives which include treating existing or residual tumor, preventing recurrence of tumor, preventing disease progression, and prolonging survival.
  • The initial clinical stage and grade remain the main determinant factors in survival regardless of the treatment.
  • Prostatic urethral mucosal involvement with bladder cancer can be effectively treated with Bacillus Calmette-Guerin (BCG) intravesical immunotherapy.
  • Intravesical chemotherapy reduces short-term tumor recurrence by about 20%, and long-term recurrence by about 7%, but has not reduced progression or mortality.
  • Presently, BCG immunotherapy remains the most effective treatment and prophylaxis for TCC (Ta, T1, CIS) and reduces tumor recurrence, disease progression, and mortality.
  • Interferons, Keyhole-limpet hemocyanin (KLH), bropirimine and Photofrin-Photodynamic Therapy (PDT) are under investigation in the management of TCC and early results are encouraging.
  • This review highlights and summarizes the recent advances in therapy for superficial TCC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. BCG Vaccine / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Cytosine / analogs & derivatives. Cytosine / therapeutic use. Dihematoporphyrin Ether / therapeutic use. Hemocyanin / therapeutic use. Humans. Interferons / therapeutic use. Photochemotherapy. Secondary Prevention

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15349563.001).
  • [ISSN] 1537-744X
  • [Journal-full-title] TheScientificWorldJournal
  • [ISO-abbreviation] ScientificWorldJournal
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCG Vaccine; 8J337D1HZY / Cytosine; 9008-11-1 / Interferons; 9013-72-3 / Hemocyanin; 97067-70-4 / Dihematoporphyrin Ether; FV4Y0JO2CX / keyhole-limpet hemocyanin; J57CTF25XJ / bropirimine
  • [Number-of-references] 81
  •  go-up   go-down


35. Fekak H, Rabu R, Joual A, Bennani S, Moufid K, Sarf S, Debragh A, el Mimu M, Benjelloun S: [Intradiverticular bladder tumors. Three case reports]. Ann Urol (Paris); 2002 Jan;36(1):53-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Les tumeurs de vessie intradiverticulaires. A propos de trois cas.
  • We reported three cases of bladder tumours in vesical diverticula, with delay of diagnosis two, eight and twelve months respectively.
  • The radiology exploration suspected the diagnosis and the histology biopsy confirmed a diagnosis of primary transitional cell carcinoma in two cases: PTa GI and T2 GII, and in an other case it was a invasive epidermoid carcinoma.
  • The first patient was dead by urethral resection of the bladder tumour.
  • The treatment consisted of radiotherapy and chemotherapy.
  • We insisted of the particularity diagnosis, histology and therapeutic for bladder tumour in vesical diverticula and the early diagnosis in order to have a good prognosis.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Diverticulum / pathology. Neoplasm Invasiveness. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11859579.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


36. Okadome A, Takeuchi F, Ishii T, Hiratsuka Y: [Tuberculous epididymitis following intravesical Bacillus Calmette-Guérin therapy]. Nihon Hinyokika Gakkai Zasshi; 2002 May;93(4):580-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tuberculous epididymitis following intravesical Bacillus Calmette-Guérin therapy].
  • Bacillus Calmette-Guérin (BCG) immunotherapy is increasingly being accepted for management of some bladder transitional cell neoplastic lesions.
  • Four months earlier he had seven treatments with intravesical BCG instillation (Tokyo 172 strain) for a grade 2 transitional cell carcinoma in situ.
  • [MeSH-minor] Administration, Intravesical. Carcinoma, Transitional Cell / drug therapy. Humans. Male. Middle Aged. Urethral Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12056045.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / BCG Vaccine
  • [Number-of-references] 14
  •  go-up   go-down


37. Saulnier-Troff FG, Busoni V, Hamaide A: A technique for resection of invasive tumors involving the trigone area of the bladder in dogs: preliminary results in two dogs. Vet Surg; 2008 Jul;37(5):427-37
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe a surgical technique for resection of the entire bladder neck, including the trigone and proximal urethra in dogs with invasive tumors causing life-threatening urinary tract obstruction.
  • METHODS: Circumferential excision of the bladder neck and proximal urethra with preservation of the neurovascular pedicles was performed to remove a rhabdomyosarcoma (dog 1) and a transitional cell carcinoma (dog 2) involving the trigone and bladder neck that were causing urinary tract obstruction.
  • Reconstruction of the bladder and proximal urethra included bilateral ureteroneocystostomy.
  • Adjuvant chemotherapy was administered postoperatively to both dogs.
  • RESULTS: Postoperatively, dogs 1 and 2 were continent after 7 and 17 days, respectively, and regained normal urinary function after resolution of a transient pollakiuria.
  • CONCLUSION: En-bloc removal of the bladder neck and proximal urethra with preservation of the dorsal vascular and nervous pedicles, although a technically challenging procedure, can be performed without associated urinary incontinence or bladder wall necrosis.
  • CLINICAL RELEVANCE: In dogs with invasive bladder tumors causing life-threatening urinary tract obstruction, resection of the bladder neck and proximal urethra should be considered as a promising surgical alternative to urinary diversion.
  • [MeSH-major] Carcinoma, Transitional Cell / veterinary. Dog Diseases / surgery. Rhabdomyosarcoma / veterinary. Urinary Bladder Neoplasms / veterinary
  • [MeSH-minor] Animals. Dogs. Female. Treatment Outcome. Urethral Obstruction / epidemiology. Urethral Obstruction / etiology. Urethral Obstruction / veterinary. Urinary Incontinence / epidemiology. Urinary Incontinence / etiology. Urinary Incontinence / veterinary. Urinary Tract / pathology. Urinary Tract / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18986309.001).
  • [ISSN] 1532-950X
  • [Journal-full-title] Veterinary surgery : VS
  • [ISO-abbreviation] Vet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Giannarini G, Kessler TM, Thoeny HC, Nguyen DP, Meissner C, Studer UE: Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution? Eur Urol; 2010 Oct;58(4):486-94
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The need for and intensity of follow-up to detect disease recurrence after radical cystectomy (RC) for transitional cell carcinoma (TCC) remains a matter for debate.
  • OBJECTIVE: To determine whether diagnosis of asymptomatic recurrence after RC by routine follow-up investigations confers a survival benefit versus symptomatic recurrence.
  • DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis of 479 patients with nonmetastatic bladder TCC receiving no neoadjuvant chemotherapy/radiation therapy and prospectively followed with a standardised protocol for a median 4.3 yr (range: 0.3-20.9) after RC at an academic tertiary referral centre.
  • The effects of age, nerve-sparing surgery, pathologic tumour stage, lymph node status, adjuvant chemotherapy, mode of recurrence diagnosis, and recurrence site on survival were assessed with multivariable Cox regression models.
  • Routine follow-up mostly detected lung metastases and urethral recurrences, while symptoms were predominantly the result of bone metastases and concomitant pelvic/distant recurrences.
  • Of 24 patients with urethral recurrences, 13 had carcinoma in situ (CIS).
  • Of these, 12 were successfully managed with urethra-sparing treatment, and 6 are still alive with no evidence of disease.
  • In multivariable analysis, mode of recurrence diagnosis and site of initial recurrence were the only independent predictors of CSS and OS.
  • Patients with recurrences detected by routine follow-up investigations and with secondary urothelial tumours as site of recurrence had a slightly but significantly higher survival probability.
  • Routine follow-up appears particularly effective in early detection of urethral CIS, which can be treated conservatively.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / surgery. Cystectomy. Ileum / transplantation. Neoplasm Recurrence, Local / diagnosis. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery. Urinary Reservoirs, Continent
  • [MeSH-minor] Aged. Early Detection of Cancer. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • [CommentIn] Eur Urol. 2010 Oct;58(4):495-7 [20609511.001]
  • (PMID = 20541311.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


39. Negro CL, De Stefanis P, Bosio A, Bisconti A, De Maria C, Charchedi M, Buffardi A, Rolle L, Fontana D: [Transvaginal repair of neobladder vaginal fistula]. Urologia; 2010 Jan-Mar;77 Suppl 16:11-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Riparazione trans-vaginale di fistola neovescico-vaginale.
  • We present our personal experience with a case of neobladder vaginal fistula.
  • Definitive pathological examination revealed pT3aN0G3 urothelial cancer with squamous aspects.
  • Two cycles of neoadjuvant chemotherapy were administered before cystectomy.
  • At first, the patient was treated conservatively, keeping the urethral catheter for two months.
  • CONCLUSION: The development of a neobladder-vaginal fistula is a significant, even if infrequent, complication after cystectomy.
  • In our case, we performed a transvaginal approach without tissue interposition, with good results.
  • Such procedure is easy and effective and, in our opinion, can be tempted as first line surgical treatment.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / surgery. Cisplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Hysterectomy, Vaginal. Middle Aged. Radiography. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21104654.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


40. Lee DJ, Rothberg MB, McKiernan JM, Benson MC, Badani KK: Robot-assisted radical cystoprostatectomy in complex surgical patients: single institution report. Can J Urol; 2009 Jun;16(3):4664-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the safety and feasibility of robotic-assisted radical cystoprostatectomy (RRCP) in a salvage setting for patients with a history of radiation and chemotherapy treatment, complex pelvic anatomy, and significant comorbidities.
  • MATERIALS AND METHODS: Over a 5 month period, six patients who met these criteria underwent RRCP for urothelial carcinoma.
  • Two of the patients had major cardiovascular disease and were previously denied an open procedure subsequently underwent chemotherapy with external beam radiation protocol.
  • One patient had brachytherapy for prior prostate cancer, and three additional patients had neoadjuvant chemotherapy with large diverticula, measuring up to 12 cm in size.
  • Four patients had pathologic pT3a disease, one patient had pT4a, and one patient had pT1 urethral squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Prostatectomy / methods. Robotics. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Male. Middle Aged. Salvage Therapy. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Can J Urol. 2009 Jun;16(3):4670 [19497176.001]
  • (PMID = 19497175.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


41. Gillitzer R, Hampel C, Wiesner C, Hadaschik B, Thüroff J: Single-institution experience with primary tumours of the male urethra. BJU Int; 2008 Apr;101(8):964-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-institution experience with primary tumours of the male urethra.
  • OBJECTIVE: To assess primary tumours of the urethra in males.
  • PATIENTS AND METHODS: We retrospectively reviewed our database from 1986 to 2006 for primary tumours of the male urethra; nine patients with primary tumours of the urethra were analysed and follow-up information was obtained.
  • RESULTS: Three patients had tumours of the prostatic urethra, two of which had proliferating focal inflammation and one a low-grade, superficial urothelial cancer.
  • Six patients had carcinoma of the bulbar or penile urethra, including two with previous local percutaneous radiotherapy for prostate cancer.
  • One patient had adjuvant chemotherapy after surgery.
  • CONCLUSION: Primary carcinoma of the male urethra is a rare entity.
  • Multimodal therapy might be required to obtain an optimum oncological outcome.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / pathology. Urethral Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Epidemiologic Methods. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070169.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


42. Borrell Palanca A, Chicote Pérez F, Alcalá-Santaella Casanova C, Cisnal Monsalve JM, Pastor Sempere F: [Studer-type orthotopic urinary bladder: our experience]. Arch Esp Urol; 2000 Dec;53(10):893-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Studer-type orthotopic urinary bladder: our experience].
  • RESULTS: Transitional cell carcinoma was found to be the most frequent histopathological type.
  • Four patients are free of disease, one died from metastatic disease and one patient with tumor progression and multiple lung metastases at two months' follow-up is currently on chemotherapy.
  • The mean operating time was significantly longer for this procedure than for the non-continent Bricker urinary diversion (mean 7.2 hours vs 3.5 hours, respectively).
  • The early and late postoperative complications were: incontinence for up to one month after removing the urethral catheter in three patients (two of these patients are still incontinent at two months' follow-up), wound infection in two and impotence in 6 patients.
  • CONCLUSION: Reservoir function in the medium-term is good; spontaneous urethral micturition and continence are maintained.
  • [MeSH-major] Carcinoma / surgery. Urinary Bladder Neoplasms / surgery. Urinary Reservoirs, Continent

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11213393.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


43. Marinkovic SP, Badlani GH: Imaging of the lower urinary tract in adults. J Endourol; 2001 Feb;15(1):75-86

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of the lower urinary tract in adults.
  • Imaging of the lower urinary tract is an integral part of everyday urologic practice.
  • Clinical application of less commonly used techniques is discussed to expand their usefulness in an ambulatory setting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11248924.001).
  • [ISSN] 0892-7790
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 59
  •  go-up   go-down


44. Manasia P, Alcaraz A, Cetina A, Alcover J: Small bladder and multiple urethral recurrences after intravesical instillation of bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder. J Urol; 2001 Feb;165(2):529-30
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bladder and multiple urethral recurrences after intravesical instillation of bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder.
  • [MeSH-major] Adjuvants, Immunologic / adverse effects. BCG Vaccine / adverse effects. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / secondary. Urethral Neoplasms / chemically induced. Urethral Neoplasms / secondary. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / secondary

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11176420.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  •  go-up   go-down


45. von der Maase H: Editorial comment on: Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur Urol; 2007 Oct;52(4):1122
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Editorial comment on: Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Urethral Neoplasms / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Kidney Neoplasms. Male. Paclitaxel / administration & dosage. Survival Analysis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Eur Urol. 2007 Oct;52(4):1115-22 [17433855.001]
  • (PMID = 17433856.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement